TY - JOUR
T1 - Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy
T2 - Safety and feasibility
AU - Corsini, Erin M.
AU - Mitchell, Kyle G.
AU - Zhou, Nicolas
AU - Bernatchez, Chantale
AU - Forget, Marie Andrée
AU - Haymaker, Cara L.
AU - Hofstetter, Wayne L.
AU - Mehran, Reza J.
AU - Rajaram, Ravi
AU - Rice, David C.
AU - Roth, Jack A.
AU - Sepesi, Boris
AU - Swisher, Stephen G.
AU - Vaporciyan, Ara A.
AU - Walsh, Garrett L.
AU - Amaria, Rodabe N.
AU - Jazaeri, Amir A.
AU - Antonoff, Mara B.
N1 - Publisher Copyright:
© 2021 Wiley Periodicals LLC
PY - 2021/9/15
Y1 - 2021/9/15
N2 - Background and Objectives: Adoptive T-cell therapies (ACTs) using expansion of tumor-infiltrating lymphocyte (TIL) populations are of great interest for advanced malignancies, with promising response rates in trial settings. However, postoperative outcomes following pulmonary TIL harvest have not been widely documented, and surgeons may be hesitant to operate in the setting of widespread disease. Methods: Patients who underwent pulmonary TIL harvest were identified, and postoperative outcomes were studied, including pulmonary, cardiovascular, infectious, and wound complications. Results: 83 patients met inclusion criteria. Pulmonary TIL harvest was undertaken primarily via a thoracoscopy with a median operative blood loss and duration of 30 ml and 65 min, respectively. The median length of stay was 2 days. Postoperative events were rare, occurring in only five (6%) patients, including two discharged with a chest tube, one discharged with oxygen, one episode of urinary retention, and one blood transfusion. No reoperations occurred. The median time from TIL harvest to ACT infusion was 37 days. Conclusions: Pulmonary TIL harvest is safe and feasible, without major postoperative events in our cohort. All patients were able to receive intended ACT infusion without delays. Therefore, thoracic surgeons should actively participate in ongoing ACT trials and aggressively seek to enroll patients on these protocols.
AB - Background and Objectives: Adoptive T-cell therapies (ACTs) using expansion of tumor-infiltrating lymphocyte (TIL) populations are of great interest for advanced malignancies, with promising response rates in trial settings. However, postoperative outcomes following pulmonary TIL harvest have not been widely documented, and surgeons may be hesitant to operate in the setting of widespread disease. Methods: Patients who underwent pulmonary TIL harvest were identified, and postoperative outcomes were studied, including pulmonary, cardiovascular, infectious, and wound complications. Results: 83 patients met inclusion criteria. Pulmonary TIL harvest was undertaken primarily via a thoracoscopy with a median operative blood loss and duration of 30 ml and 65 min, respectively. The median length of stay was 2 days. Postoperative events were rare, occurring in only five (6%) patients, including two discharged with a chest tube, one discharged with oxygen, one episode of urinary retention, and one blood transfusion. No reoperations occurred. The median time from TIL harvest to ACT infusion was 37 days. Conclusions: Pulmonary TIL harvest is safe and feasible, without major postoperative events in our cohort. All patients were able to receive intended ACT infusion without delays. Therefore, thoracic surgeons should actively participate in ongoing ACT trials and aggressively seek to enroll patients on these protocols.
KW - adoptive cell therapy
KW - postoperative outcomes
KW - pulmonary metastasectomy
KW - pulmonary resection
KW - tumor-infiltrating lymphocyte
UR - http://www.scopus.com/inward/record.url?scp=85107013142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107013142&partnerID=8YFLogxK
U2 - 10.1002/jso.26548
DO - 10.1002/jso.26548
M3 - Article
C2 - 34057733
AN - SCOPUS:85107013142
SN - 0022-4790
VL - 124
SP - 699
EP - 703
JO - Journal of surgical oncology
JF - Journal of surgical oncology
IS - 4
ER -